Twist Bioscience director granted 5,095-share award

Twist Bioscience director Keith Crandell received an annual equity award of 5,095 shares of common stock on February 5, 2026 at a price of $0 per share.

Rhea-AI Filing Summary

Twist Bioscience director Keith Crandell received an annual equity award of 5,095 shares of common stock on February 5, 2026 at a price of $0 per share. After this grant, he directly owns 27,571 shares of Twist Bioscience common stock.

These annual award shares will fully vest on the earlier of the one-year anniversary of the grant date or the first annual shareholder meeting after the grant, as long as he continues serving as a non‑employee director. In addition, 76,047 shares are held indirectly through the Keith L. Crandell Trust, for which he and his spouse are co‑trustees and he is the sole beneficiary.

Insider Trade Summary

Grant/Award: 5,095 shares

Grant/Award 2 txns

Insider CRANDELL KEITH

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,095	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 27,571 shares (Direct); Common Stock — 76,047 shares (Indirect, By Keith L. Crandell Trust)

Footnotes (2)

1. F1. 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date.
2. F2. The Reporting Person and his spouse are co-trustees. The Reporting Person is the sole beneficiary of the Keith L. Crandell Trust.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Twist Bioscience (TWST) director Keith Crandell report in this Form 4 filing?

Keith Crandell reported receiving an annual equity award of 5,095 shares of Twist Bioscience common stock on February 5, 2026. The shares were granted at $0 per share, increasing his directly held position to 27,571 shares after the transaction.

How many Twist Bioscience (TWST) shares does Keith Crandell own after this grant?

After the grant, Keith Crandell directly owns 27,571 shares of Twist Bioscience common stock. The filing also reports 76,047 additional shares held indirectly through the Keith L. Crandell Trust, where he and his spouse are co‑trustees and he is the sole beneficiary.

What are the vesting terms of Keith Crandell’s 5,095-share equity award at Twist Bioscience (TWST)?

The 5,095-share annual equity award vests 100% on the earlier of the one‑year anniversary of the grant date or the first annual shareholder meeting after the grant. Vesting requires that he remain a non‑employee director and service provider on the applicable vesting date.

How are the indirect Twist Bioscience (TWST) shares held for Keith Crandell structured?

An additional 76,047 Twist Bioscience shares are reported as held indirectly by the Keith L. Crandell Trust. According to the filing, Crandell and his spouse serve as co‑trustees, and he is described as the sole beneficiary of this trust structure.

Did Keith Crandell pay cash for the 5,095 Twist Bioscience (TWST) shares reported in this Form 4?

No cash was paid for this award; the 5,095 Twist Bioscience shares were granted at a reported price of $0 per share. This reflects an equity compensation grant to a non‑employee director rather than an open‑market stock purchase transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/09/2026 - 05:34 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CRANDELL KEITH

(Last) (First) (Middle)

8755 W. HIGGINS ROAD, SUITE 1025

(Street)

CHICAGO IL 60631

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/05/2026		A		5,095(1)	A	$0	27,571	D
Common Stock								76,047	I	By Keith L. Crandell Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date.

2. The Reporting Person and his spouse are co-trustees. The Reporting Person is the sole beneficiary of the Keith L. Crandell Trust.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Keith Crandell	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.